TABLE 1.
Characteristics of people with HIV in fiscal year 2022† by district type and total.
| Variable | Urban (n = 53 234) |
Rural (n = 51 625) |
All PWH (N = 104 859) |
|||
|---|---|---|---|---|---|---|
| n | % | n | % | N | % | |
| Sex | ||||||
| Female | 36 100 | 67.8 | 35 980 | 69.7 | 72 080 | 68.7 |
| Male | 17 134 | 32.2 | 15 645 | 30.3 | 32 779 | 31.3 |
| Age (years) | ||||||
| 5–14 | 975 | 1.8 | 1016 | 2.0 | 1991 | 1.9 |
| 15–24 | 8782 | 16.5 | 8364 | 16.2 | 17 146 | 16.4 |
| 25–34 | 15 800 | 29.7 | 15 042 | 29.1 | 30 842 | 29.4 |
| 35–44 | 12 600 | 23.7 | 12 302 | 23.8 | 24 902 | 23.7 |
| 45–54 | 6608 | 12.4 | 6560 | 12.7 | 13 168 | 12.6 |
| 55–64 | 4334 | 8.1 | 4188 | 8.1 | 8522 | 8.1 |
| 65+ | 4135 | 7.8 | 4153 | 8.0 | 8288 | 7.9 |
| ART status | ||||||
| Starting ART | 4359 | 8.2 | 3357 | 6.5 | 7716 | 7.4 |
| Already on ART | 48 875 | 91.8 | 48 268 | 93.5 | 97 143 | 92.6 |
| ART delivery model | ||||||
| SoC‡ | 5029 | 9.4 | 6874 | 13.3 | 11 903 | 11.4 |
| MMD | 17 283 | 32.5 | 12 330 | 23.9 | 29 613 | 28.2 |
| DMoC | 30 922 | 58.1 | 32 421 | 62.8 | 63 343 | 60.4 |
| W4SS done | ||||||
| Yes | 53 216 | 100.0 | 50 808 | 98.4 | 104 024 | 99.2 |
| No | 18 | 0.0 | 817 | 1.6 | 835 | 0.8 |
| W4SS result | ||||||
| Positive | 2880 | 5.4 | 2391 | 4.6 | 5271 | 5.0 |
| Negative | 50 336 | 94.6 | 48 417 | 93.8 | 98 753 | 94.2 |
| Not applicable | 18 | 0.0 | 817 | 1.6 | 835 | 0.8 |
| Previous TB | ||||||
| Yes | 949 | 1.8 | 406 | 0.8 | 1355 | 1.3 |
| No | 52 285 | 98.2 | 51 219 | 99.2 | 103 504 | 98.7 |
| Viral load test done | ||||||
| Yes | 45 181 | 84.9 | 42 354 | 82.0 | 87 535 | 83.5 |
| No | 8053 | 15.1 | 9271 | 18.0 | 17 324 | 16.5 |
ART, antiretroviral therapy; SoC, standard of care; MMD, multi-month dispensing; DMoC, differentiated models of care; W4SS, WHO Four Symptom Screen; PWH, people with HIV; TB, tuberculosis.
†
, fiscal year 2022: 01 October 2021 – 30 September 2022;
‡
, Most individuals in SoC were initiating ART (‘Starting ART’), consistent with clinical practice in which new ART patients attend monthly visits during early treatment.